Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

SeiichiroOzono; TaijiTsukamoto; SeijiNaito; YasuoOhashi; TakeshiUeda; TsutomuNishiyama; HidekiMaeda; HidehitoKusuoka; RioAkazawa; MototsuguIto; HideyukiAkaza

首页> 外文期刊>Japanese journal of clinical oncology. >Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

【24h】

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

机译：日本前列腺癌患者的3个月给药方案的疗效和安全性：II期维持剂量查找研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The 3-month dosing regimen of degarelix with maintenance doses of 360 and 480 mg was effective and safe for the treatment of Japanese patients with prostate cancer.

机译：维持剂量为360和480毫克维持剂量的3个月给药方案是有效和安全的，用于治疗日本前列腺癌患者。

著录项

来源
《Japanese journal of clinical oncology.》 |2017年第5期|共9页
作者
SeiichiroOzono; TaijiTsukamoto; SeijiNaito; YasuoOhashi; TakeshiUeda; TsutomuNishiyama; HidekiMaeda; HidehitoKusuoka; RioAkazawa; MototsuguIto; HideyukiAkaza;
展开▼
作者单位

Hamamatsu University School of Medicine;

Sapporo Medical University;

Chuo University;

Niigata University Medical and Dental Hospital;

The University of Tokyo;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
clinical trial; gonadotropin-releasing hormone antagonist; degarelix; Japan; prostate cancer;

机译：临床试验;促性腺激素 - 释放激素拮抗剂;Degarelix;日本;前列腺癌;
入库时间 2022-08-20 08:40:53

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study [J] . SeiichiroOzono, TaijiTsukamoto, SeijiNaito, Japanese journal of clinical oncology. . 2017,第5期

机译：日本前列腺癌患者的3个月给药方案的疗效和安全性：II期维持剂量查找研究
2. The efficacy and safety of degarelix, a GnRH antagonist: A 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer [J] . OzonoS., UedaT., HoshiS., Japanese journal of clinical oncology. . 2012,第6期

机译：degarelix（一种GnRH拮抗剂）的疗效和安全性：一项针对日本前列腺癌患者的12个月，多中心，随机，维持剂量寻找II期研究
3. The Efficacy and Safety of Degarelix, a GnRH Antagonist: A 12-month, Multicentre, Randomized, Maintenance Dose-finding Phasen II Study in Japanese Patients with Prostate Cancer [J] . Hideyuki Akaza Japanese Journal of Clinical Oncology . 2012,第6期

机译：GnRH拮抗剂Degarelix的功效和安全性：一项针对日本前列腺癌患者的12个月，多中心，随机，维持剂量寻找Phasen II研究
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study [O] . Seiichiro Ozono, Taiji Tsukamoto, Seiji Naito, -1

机译：在日本前列腺癌患者中使用地加瑞克3个月给药方案的疗效和安全性：II期维持剂量研究
7. The Efficacy and Safety of Degarelix, a GnRH Antagonist: A 12-month, Multicentre, Randomized, Maintenance Dose-finding Phase II Study in Japanese Patients with Prostate Cancer [O] . S. Ozono, T. Ueda, S. Hoshi, 2012

机译：Degarelix，GNRH拮抗剂：12个月，多期，随机，维持剂量发现期二期研究日本前列腺癌的疗效和安全性

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

摘要

著录项

相似文献

相关主题

期刊订阅